2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
This guideline cites 17 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2026
- Source
- Ndumele CE, Rodriguez F, et al. Circulation. 2026;153. Published online 9 June 2026; simultaneously J Am Coll Cardiol. 2026;87(22S):e1889–e2007.doi 10.1161/CIR.0000000000001453
The first guideline of its kind: obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease are handled as one syndrome staged from 0 to 4, and the document retires and absorbs the 2013 AHA/ACC/TOS obesity guideline. There is no European equivalent — the ESC distributes this territory across its 2023 diabetes, 2021 prevention and (with the kidney societies) KDIGO documents — so the CKM guideline is less a divergence from the ESC than a structural reorganisation of the same evidence, with obesity itself, and incretin-based therapy for it, moved from the margins to the centre. Cardioprotective and kidney-protective drug classes are recommended by CKM stage rather than by the specialty that happens to own the patient. The register's cardiometabolic, kidney and heart-failure trials are grouped below.
Obesity & incretin-based therapy7
- 2025SURMOUNT-5Cardiology · Cardiometabolic · GIP/GLP-1 RAIn 751 adults with obesity but without type 2 diabetes, tirzepatide reduced body weight at 72 weeks more than semaglutide (-20.2% vs -13.7%).-20.2% vs -13.7%Read →
- 2025SUMMITCardiology · Cardiometabolic · Obesity & HFpEFIn 731 patients with HFpEF and obesity, tirzepatide reduced cardiovascular death or worsening heart failure compared with placebo.HR 0.62Read →
- 2025SOULCardiology · Cardiometabolic · oral GLP-1 RAIn 9,650 patients with type 2 diabetes and ASCVD, CKD, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo (HR 0.86, 95% CI 0.77-0.96).HR 0.8695% CI 0.77-0.96Read →
- 2023SELECT CoreCardiology · Cardiometabolic · GLP-1 RAIn 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.HR 0.8Read →
- 2023STEP-HFpEFCardiology · HF · GLP-1 RAIn 529 patients with HFpEF (EF ≥ 45%) and obesity (BMI ≥ 30) without diabetes, semaglutide 2.4 mg improved heart-failure symptoms (KCCQ) and body weight compared with placebo.Read →
- 2021STEP 1Endocrinology · Obesity · Semaglutide for obesityIn 1,961 adults with overweight or obesity without type 2 diabetes, subcutaneous semaglutide 2.4 mg weekly reduced body weight at 68 weeks compared with placebo.-14.9% vs -2.4%Read →
- 2016LEADERCardiology · Cardiometabolic · GLP-1 RAIn 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
SGLT2 inhibitors: cardiovascular outcomes2
- 2019DECLARE-TIMI 58Cardiology · Cardiometabolic · SGLT2 inhibitorsIn 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.83Read →
- 2015EMPA-REG OUTCOME CoreCardiology · Cardiometabolic · SGLT2 inhibitorsIn 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.HR 0.86Read →
Kidney protection3
- 2024FLOW CoreNephrology · CKD · GLP-1 RAIn 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.HR 0.7695% CI 0.66-0.88Read →
- 2020DAPA-CKD CoreNephrology · CKD · SGLT2 inhibitorsIn 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.HR 0.6195% CI 0.51-0.72Read →
- 2019CREDENCE CoreNephrology · CKD · SGLT2 inhibitorsIn 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.HR 0.7095% CI 0.59-0.82Read →
Heart failure across the CKM spectrum5
- 2024FINEARTS-HFCardiology · HF · MRAIn 6,001 patients with heart failure and an ejection fraction ≥ 40 %, finerenone reduced worsening-heart-failure events and cardiovascular death compared with placebo.IRR 0.84Read →
- 2022DELIVERCardiology · HF · SGLT2 inhibitorsIn 6,263 patients with heart failure and an ejection fraction > 40 %, dapagliflozin reduced worsening heart failure or cardiovascular death compared with placebo.HR 0.82Read →
- 2021EMPEROR-Preserved CoreCardiology · HF · SGLT2 inhibitorsIn 5,988 patients with HFpEF (EF > 40 %), empagliflozin reduced HF hospitalisation or CV death compared with placebo.HR 0.7995% CI 0.69-0.90Read →
- 2020EMPEROR-ReducedCardiology · HF · SGLT2 inhibitorsIn 3,730 patients with HFrEF (EF ≤ 40 %), empagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.75Read →
- 2019DAPA-HF CoreCardiology · HF · SGLT2 inhibitorsIn 4,744 patients with HFrEF (with or without diabetes), dapagliflozin reduced worsening HF or CV death versus placebo.HR 0.74Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2022SURMOUNT-1
Tirzepatide for weight reduction in obesity without diabetes.
- 2021FIDELIO-DKD / FIGARO-DKD
Finerenone in diabetic kidney disease — kidney and cardiovascular protection.
- 2023EMPA-KIDNEY
Empagliflozin across the chronic kidney disease spectrum, with and without diabetes.
- 2013Look AHEAD
Intensive lifestyle intervention in type 2 diabetes — weight loss without a reduction in cardiovascular events.
- 2021STEP 2 / STEP 8
Semaglutide for obesity in type 2 diabetes and against liraglutide — the dose-finding context for the register's STEP 1.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.